Nevertheless, the Rac1 inhibitor treatment effectively reversed the effect of DOCK1 overexpression on GTP-Rac1 complex abundance, meaning DOCK1 could directly promote the activation of Rac1 in AML cells (Fig. 6B). Here, RAC1 is linked to acute myeloid leukemia.